Mahmoud Obeidat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahmoud Obeidat has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Péter Hegyi
Translational Pancreatology Research Group Interdisciplinary Center of Excellence for Research Development and Innovation University of Szeged Szeged Hungary
10 shared publications Péter Hegyi
Centre for Translational Medicine, Semmelweis University, Budapest, 1085, Hungary; Institute of Pancreatic Diseases, Semmelweis University, Budapest, 1083, Hungary; Institute for Translational Medicine, Medical School, University of Pécs, Pecs, 7623, Hungary; Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation, University of Szeged, Szeged, 6725, Hungary
6 shared publications- Bálint Erőss
Institute for Translational Medicine Medical School University of Pécs Pécs Hungary
4 shared publications - Boglárka Lilla Szentes
Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
3 shared publications Brigitta Teutsch
Centre for Translational Medicine, Semmelweis University, Budapest, Hungary; Department of Radiology, Medical Imaging Centre, Semmelweis University, Budapest, Hungary; Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
3 shared publicationsSzilvia Kiss-Dala
Affiliation Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in EBioMedicine
- Vol. 133, 106528
Prognostic value of microRNA expression in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
- 23 October 2026
- Published by Elsevier in EBioMedicine
- Vol. 133, 106528
Open AccessPrognostic value of microRNA expression in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
- Open Access
- 1 September 2026
- Published by Wiley in BJU International
Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC
Background and Objective: Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials between androgen receptor pathway inhibitor‐based doublets are lacking. Methods: Our systematic search was conducted on 22 September 2025, in PubMed, Embase, and the Cochrane Library databases. Studies including patients with mHSPC treated with APA, ABI, or ENZA plus ADT were eligible if they contained real‐world data and reported at least one outcome: overall survival (OS), PSA50, PSA90, PSA ≤0.2 ng/mL, time to castration‐resistant prostate cancer, biochemical progression‐free survival, grade ≥3 adverse events, or treatment discontinuation (TDC). Pooled hazard ratios (HRs) and odds ratios (ORs) were calculated using inverse variance random‐effects models. Key Findings and Limitations: In total, 17 retrospective studies comprising 18 626 patients were included. Compared with ABI, APA was associated with improved OS (HR 1.27; 95% confidence interval [CI] 1.09–1.47; P = 0.002), PSA90 (OR 0.70; 95% CI 0.54–0.91; P = 0.019), PSA P = 0.039), and castration‐resistant prostate cancer (HR 1.40; 95% CI 1.05–1.88; P = 0.023). APA also demonstrated higher PSA90 response rates than ENZA (OR 0.67; 95% CI 0.5–0.9; P = 0.017). TDC due to adverse events was lower with ABI than with APA (OR 0.56; 95% CI 0.37–0.86; P = 0.029), with no significant difference between ENZA and APA ( P = 0.10). Conclusions and Clinical Implications: In real‐world settings, APA‐based doublets were associated with more favourable efficacy outcomes with ABI, whereas ABI‐ and ENZA‐based regimens were associated with lower TDC rates. ABI and ENZA demonstrated comparable efficacy and safety profiles, supporting individualized ARPI selection in mHSPC.
- 1 September 2026
- Published by Wiley in BJU International
Open AccessComparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC
Background and Objective: Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials between androgen receptor pathway inhibitor‐based doublets are lacking. Methods: Our systematic search was conducted on 22 September 2025, in PubMed, Embase, and the Cochrane Library databases. Studies including patients with mHSPC treated with APA, ABI, or ENZA plus ADT were eligible if they contained real‐world data and reported at least one outcome: overall survival (OS), PSA50, PSA90, PSA ≤0.2 ng/mL, time to castration‐resistant prostate cancer, biochemical progression‐free survival, grade ≥3 adverse events, or treatment discontinuation (TDC). Pooled hazard ratios (HRs) and odds ratios (ORs) were calculated using inverse variance random‐effects models. Key Findings and Limitations: In total, 17 retrospective studies comprising 18 626 patients were included. Compared with ABI, APA was associated with improved OS (HR 1.27; 95% confidence interval [CI] 1.09–1.47; P = 0.002), PSA90 (OR 0.70; 95% CI 0.54–0.91; P = 0.019), PSA P = 0.039), and castration‐resistant prostate cancer (HR 1.40; 95% CI 1.05–1.88; P = 0.023). APA also demonstrated higher PSA90 response rates than ENZA (OR 0.67; 95% CI 0.5–0.9; P = 0.017). TDC due to adverse events was lower with ABI than with APA (OR 0.56; 95% CI 0.37–0.86; P = 0.029), with no significant difference between ENZA and APA ( P = 0.10). Conclusions and Clinical Implications: In real‐world settings, APA‐based doublets were associated with more favourable efficacy outcomes with ABI, whereas ABI‐ and ENZA‐based regimens were associated with lower TDC rates. ABI and ENZA demonstrated comparable efficacy and safety profiles, supporting individualized ARPI selection in mHSPC.
- Open Access
- 15 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Primary tumor resection prior to peptide receptor radionuclide therapy is associated with improved survival in metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis
The role of primary tumor resection (PTR) in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing peptide receptor radionuclide therapy (PRRT) remains uncertain. This meta-analysis evaluated whether PTR prior to PRRT is associated with improved survival outcomes compared to PRRT alone. MEDLINE, Embase, and the Cochrane Library were searched through November 19, 2024 (PROSPERO CRD42024605382). Eligible studies included metastatic GEP-NET patients treated with PRRT, with or without prior PTR. Data extraction was performed independently in duplicate following PRISMA guidelines. Risk of bias was assessed using the QUIPS tool. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were pooled using random-effects models. Five observational studies, involving 1,186 patients (649 with PTR before PRRT; 537 receiving PRRT alone), met the inclusion criteria. PTR prior to PRRT was associated with longer PFS (HR, 0.62; 95% CI, 0.42–0.91; I² = 45%) and OS (HR, 0.46; 95% CI, 0.33–0.65; I² = 0%). Given the observational design, confounding by indication and potential immortal-time bias were the primary sources of bias, though the overall risk was rated low to moderate. PTR before PRRT was associated with longer PFS and OS in metastatic, somatostatin receptor–positive GEP-NETs. These findings may indicate an association, but the low certainty of the observational evidence limits their interpretability. Future well-designed studies are required to confirm or refute this observation.
- 15 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPrimary tumor resection prior to peptide receptor radionuclide therapy is associated with improved survival in metastatic gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis
The role of primary tumor resection (PTR) in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) undergoing peptide receptor radionuclide therapy (PRRT) remains uncertain. This meta-analysis evaluated whether PTR prior to PRRT is associated with improved survival outcomes compared to PRRT alone. MEDLINE, Embase, and the Cochrane Library were searched through November 19, 2024 (PROSPERO CRD42024605382). Eligible studies included metastatic GEP-NET patients treated with PRRT, with or without prior PTR. Data extraction was performed independently in duplicate following PRISMA guidelines. Risk of bias was assessed using the QUIPS tool. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were pooled using random-effects models. Five observational studies, involving 1,186 patients (649 with PTR before PRRT; 537 receiving PRRT alone), met the inclusion criteria. PTR prior to PRRT was associated with longer PFS (HR, 0.62; 95% CI, 0.42–0.91; I² = 45%) and OS (HR, 0.46; 95% CI, 0.33–0.65; I² = 0%). Given the observational design, confounding by indication and potential immortal-time bias were the primary sources of bias, though the overall risk was rated low to moderate. PTR before PRRT was associated with longer PFS and OS in metastatic, somatostatin receptor–positive GEP-NETs. These findings may indicate an association, but the low certainty of the observational evidence limits their interpretability. Future well-designed studies are required to confirm or refute this observation.
- Open Access
- 7 May 2026
- Published by Elsevier in SSRN Electronic Journal
Pancreas and Islet Transplantation versus Insulin Therapy in Patients with Type 1 Diabetes undergoing Renal Transplantation: A Systematic Review and Meta-Analysis
Introduction: We aimed to compare the efficacy of pancreas transplantation, islet transplantation, and insulin therapy in patients with type 1 diabetes mellitus (T1DM) undergoing renal transplantation. Methods: We conducted a systematic search across three databases on November 26, 2024 for studies on simultaneous pancreas-kidney transplant (SPKT), pancreas-after-kidney (PAK), simultaneous islet-kidney (SIK), islet-after-kidney (IAK), and kidney transplant alone with insulin (KTA-I) in T1DM. We analyzed changes in glycated hemoglobin (HbA1c %) from baseline, as well as other glucose metabolism, renal, and cardiovascular parameters. Pooled single means or mean differences (MD) were calculated with 95% confidence intervals (CIs). Overall survival (OS) and graft survival were assessed using the restricted mean survival time, derived from Kaplan-Meier curves at the truncated time. Results: We included 286 studies in the systematic review and 142 in the meta-analysis. We found that SPKT offers a greater reduction in HbA1c than KTA-I (MD:-3·2; CI:-5·26, -1·14) after 3 years. At 12 months, mean C-peptide (ng/mL) levels were higher after SPKT than after SIK/IAK (2·76 CI:2·49, 3·02 vs. 1·54 CI:0·16, 2·92). At 60 months after transplantation, OS was similar for SPKT, PAK, and KTA-I, whereas SIK/IAK was associated with the lowest OS (P=0·0095). At 120 months, overall and kidney graft survival were higher in LDK than DDK, and LDK was not inferior to SPKT. Pancreas graft survival was higher after SPKT than PAK (P=0·0018). Interpretation: Pancreas transplantation provides the best glucose metabolism. LDK offers higher graft survival than DDK and is comparable to SPKT, which in turn offers better pancreas graft survival than PAK. Islet transplantation is associated with the lowest OS.
- 7 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPancreas and Islet Transplantation versus Insulin Therapy in Patients with Type 1 Diabetes undergoing Renal Transplantation: A Systematic Review and Meta-Analysis
Introduction: We aimed to compare the efficacy of pancreas transplantation, islet transplantation, and insulin therapy in patients with type 1 diabetes mellitus (T1DM) undergoing renal transplantation. Methods: We conducted a systematic search across three databases on November 26, 2024 for studies on simultaneous pancreas-kidney transplant (SPKT), pancreas-after-kidney (PAK), simultaneous islet-kidney (SIK), islet-after-kidney (IAK), and kidney transplant alone with insulin (KTA-I) in T1DM. We analyzed changes in glycated hemoglobin (HbA1c %) from baseline, as well as other glucose metabolism, renal, and cardiovascular parameters. Pooled single means or mean differences (MD) were calculated with 95% confidence intervals (CIs). Overall survival (OS) and graft survival were assessed using the restricted mean survival time, derived from Kaplan-Meier curves at the truncated time. Results: We included 286 studies in the systematic review and 142 in the meta-analysis. We found that SPKT offers a greater reduction in HbA1c than KTA-I (MD:-3·2; CI:-5·26, -1·14) after 3 years. At 12 months, mean C-peptide (ng/mL) levels were higher after SPKT than after SIK/IAK (2·76 CI:2·49, 3·02 vs. 1·54 CI:0·16, 2·92). At 60 months after transplantation, OS was similar for SPKT, PAK, and KTA-I, whereas SIK/IAK was associated with the lowest OS (P=0·0095). At 120 months, overall and kidney graft survival were higher in LDK than DDK, and LDK was not inferior to SPKT. Pancreas graft survival was higher after SPKT than PAK (P=0·0018). Interpretation: Pancreas transplantation provides the best glucose metabolism. LDK offers higher graft survival than DDK and is comparable to SPKT, which in turn offers better pancreas graft survival than PAK. Islet transplantation is associated with the lowest OS.
- Open Access
- 1 May 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Clinical practice patterns in the pre-endoscopic management of individuals presenting with acute upper gastrointestinal bleeding: results of an international survey
Background: Despite recent guideline recommendations on managing acute upper gastrointestinal bleeding (AUGIB), mortality rates have not substantially improved over the years. Objectives: We aimed to understand real-life pre-endoscopic assessment and management practices in AUGIB. Design: We conducted an international online survey from April to November 2023. Methods: Key domains captured respondents’ demographics and clinical practice location, definitions of hemodynamic instability, and pre-endoscopic assessment. We provided descriptive proportions of responses. Secondary analyses explored differences in responses based on years of clinical experience. Results: Among the 533 clinicians who completed the survey, 47.1% reported using a triage system for AUGIB, and only 60.4% applied risk stratification scores at the time of presentation. Normal saline and balanced crystalloid fluids were almost equally preferred for initial fluid resuscitation. Hemodynamically unstable patients were typically managed in emergency departments and/or intensive care units. Over 85% of respondents followed a restrictive blood transfusion strategy in stable patients, but this dropped to 50.3% in hemodynamically unstable cases. Among respondents, 34.3% did not routinely use prokinetics, and 27.6% avoided their use, even in cases of severe bleeding or suspected gastric emptying disorders. The majority (87.1%) prescribed proton pump inhibitors before endoscopy. For suspected variceal bleeding, 83.7% reported using vasoactive agents, and 74.3% reported administering prophylactic antibiotics. Younger clinicians were more likely to follow recent guidelines than those with over 15 years of clinical experience. Conclusion: We found considerable variation in the pre-endoscopic management of individuals with AUGIB. Overall adherence to international guidelines was inconsistent, which may have implications for patient outcomes.
- 1 May 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Open AccessClinical practice patterns in the pre-endoscopic management of individuals presenting with acute upper gastrointestinal bleeding: results of an international survey
Background: Despite recent guideline recommendations on managing acute upper gastrointestinal bleeding (AUGIB), mortality rates have not substantially improved over the years. Objectives: We aimed to understand real-life pre-endoscopic assessment and management practices in AUGIB. Design: We conducted an international online survey from April to November 2023. Methods: Key domains captured respondents’ demographics and clinical practice location, definitions of hemodynamic instability, and pre-endoscopic assessment. We provided descriptive proportions of responses. Secondary analyses explored differences in responses based on years of clinical experience. Results: Among the 533 clinicians who completed the survey, 47.1% reported using a triage system for AUGIB, and only 60.4% applied risk stratification scores at the time of presentation. Normal saline and balanced crystalloid fluids were almost equally preferred for initial fluid resuscitation. Hemodynamically unstable patients were typically managed in emergency departments and/or intensive care units. Over 85% of respondents followed a restrictive blood transfusion strategy in stable patients, but this dropped to 50.3% in hemodynamically unstable cases. Among respondents, 34.3% did not routinely use prokinetics, and 27.6% avoided their use, even in cases of severe bleeding or suspected gastric emptying disorders. The majority (87.1%) prescribed proton pump inhibitors before endoscopy. For suspected variceal bleeding, 83.7% reported using vasoactive agents, and 74.3% reported administering prophylactic antibiotics. Younger clinicians were more likely to follow recent guidelines than those with over 15 years of clinical experience. Conclusion: We found considerable variation in the pre-endoscopic management of individuals with AUGIB. Overall adherence to international guidelines was inconsistent, which may have implications for patient outcomes.
- Open Access
Comparative Effectiveness of Pharmacological and Non-Pharmacological Interventions for Nausea and Vomiting in Pregnancy: A Systematic Review and Network Meta-Analysis
Background: Nausea and vomiting in pregnancy affects up to 80% of pregnant women and may progress to hyperemesis gravidarum, leading to maternal morbidity and adverse pregnancy outcomes. Despite numerous pharmacological and non-pharmacological options, the comparative efficacy and safety of these interventions remain unclear. Methods: We conducted a systematic review and network meta-analysis of randomized controlled trials assessing pharmacological and non-pharmacological interventions for nausea and vomiting in pregnancy. The databases searched included CENTRAL, PubMed, and EMBASE (up to 28 May 2024). Eligible trials compared interventions with a placebo in pregnant women with nausea and vomiting in pregnancy. The primary outcomes were symptom severity, assessed using validated tools. Safety outcomes included adverse effects. Data were pooled using frequentist pairwise and network meta-analyses. The risk of bias was assessed using the RoB2 tool, and the certainty of evidence was evaluated using the CINeMA framework. Results: Of 9844 records screened, 24 randomized controlled trials (3017 participants) met the inclusion criteria, encompassing 16 intervention categories. Network analysis ranked quince, vitamin B6 with pomegranate and mint, acupressure P6, dimenhydrinate, and acupuncture combined with doxylamine–pyridoxine as the most effective interventions for reducing symptoms of nausea and vomiting in pregnancy, with considerable uncertainty and low-to-moderate quality of evidence. Reporting of adverse events was limited. Risk of bias was low to moderate. Discussion: Most interventions demonstrated significant benefit over a placebo. However, high heterogeneity and sparse reporting of adverse effects warrant caution when translating these results into clinical practice. Conclusions: This study indicates that both pharmacological (vitamin B6, metoclopramide, dimenhydrinate) and non-pharmacological (ginger, quince, acupressure, acupuncture) interventions might be effective in reducing symptoms of nausea and vomiting in pregnancy.
Open AccessComparative Effectiveness of Pharmacological and Non-Pharmacological Interventions for Nausea and Vomiting in Pregnancy: A Systematic Review and Network Meta-Analysis
Background: Nausea and vomiting in pregnancy affects up to 80% of pregnant women and may progress to hyperemesis gravidarum, leading to maternal morbidity and adverse pregnancy outcomes. Despite numerous pharmacological and non-pharmacological options, the comparative efficacy and safety of these interventions remain unclear. Methods: We conducted a systematic review and network meta-analysis of randomized controlled trials assessing pharmacological and non-pharmacological interventions for nausea and vomiting in pregnancy. The databases searched included CENTRAL, PubMed, and EMBASE (up to 28 May 2024). Eligible trials compared interventions with a placebo in pregnant women with nausea and vomiting in pregnancy. The primary outcomes were symptom severity, assessed using validated tools. Safety outcomes included adverse effects. Data were pooled using frequentist pairwise and network meta-analyses. The risk of bias was assessed using the RoB2 tool, and the certainty of evidence was evaluated using the CINeMA framework. Results: Of 9844 records screened, 24 randomized controlled trials (3017 participants) met the inclusion criteria, encompassing 16 intervention categories. Network analysis ranked quince, vitamin B6 with pomegranate and mint, acupressure P6, dimenhydrinate, and acupuncture combined with doxylamine–pyridoxine as the most effective interventions for reducing symptoms of nausea and vomiting in pregnancy, with considerable uncertainty and low-to-moderate quality of evidence. Reporting of adverse events was limited. Risk of bias was low to moderate. Discussion: Most interventions demonstrated significant benefit over a placebo. However, high heterogeneity and sparse reporting of adverse effects warrant caution when translating these results into clinical practice. Conclusions: This study indicates that both pharmacological (vitamin B6, metoclopramide, dimenhydrinate) and non-pharmacological (ginger, quince, acupressure, acupuncture) interventions might be effective in reducing symptoms of nausea and vomiting in pregnancy.
- Open Access
Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies
Background/Objectives: Cardiovascular diseases (CVDs) frequently limit the feasibility and effectiveness of cancer treatment. However, CVD burden has not been comprehensively described in pancreatic cancer. In our systematic review and meta-analysis, we evaluated the prevalence and incidence of CVDs in pancreatic ductal adenocarcinoma (PDAC). Methods: We conducted the systematic search in PubMed, EMBASE, and CENTRAL on 5 February 2024. Studies reporting the prevalence or incidence of CVDs in PDAC were included. Subgroup analyses were performed based on cancer stage and treatment type. Pooled proportions with the 95% confidence interval (CI) were calculated using a random-effects model. (PROSPERO: CRD42023482295). Results: We included 197 articles. At PDAC diagnosis, non-thrombotic cardiovascular diseases (NT-CVDs) were as prevalent as in the general population: hypertension in 33% (CI: 27–40%), ischemic heart disease in 6% (CI: 3–12%), and heart failure, arrhythmia, and stroke each in 2–3%. Their incidence during treatment remained low (1–10%). Thrombotic events, excluding pulmonary embolism, were present in 11% (CI: 7–15%) at diagnosis, with an incidence of 8–10% regardless of stage or treatment. Pulmonary embolism affected 3% at diagnosis and occurred at a similar rate during treatment. Conclusions: Thromboembolic events are common in PDAC and occur both at diagnosis and during follow-up. Their incidence remains stable across treatment modalities and disease stages, suggesting that the tumor itself is the primary driver of thrombotic risk. The prevalence of NT-CVDs in PDAC is comparable to that in the general population and shows minimal variation across cancer stages or treatment modalities.
Open AccessCardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies
Background/Objectives: Cardiovascular diseases (CVDs) frequently limit the feasibility and effectiveness of cancer treatment. However, CVD burden has not been comprehensively described in pancreatic cancer. In our systematic review and meta-analysis, we evaluated the prevalence and incidence of CVDs in pancreatic ductal adenocarcinoma (PDAC). Methods: We conducted the systematic search in PubMed, EMBASE, and CENTRAL on 5 February 2024. Studies reporting the prevalence or incidence of CVDs in PDAC were included. Subgroup analyses were performed based on cancer stage and treatment type. Pooled proportions with the 95% confidence interval (CI) were calculated using a random-effects model. (PROSPERO: CRD42023482295). Results: We included 197 articles. At PDAC diagnosis, non-thrombotic cardiovascular diseases (NT-CVDs) were as prevalent as in the general population: hypertension in 33% (CI: 27–40%), ischemic heart disease in 6% (CI: 3–12%), and heart failure, arrhythmia, and stroke each in 2–3%. Their incidence during treatment remained low (1–10%). Thrombotic events, excluding pulmonary embolism, were present in 11% (CI: 7–15%) at diagnosis, with an incidence of 8–10% regardless of stage or treatment. Pulmonary embolism affected 3% at diagnosis and occurred at a similar rate during treatment. Conclusions: Thromboembolic events are common in PDAC and occur both at diagnosis and during follow-up. Their incidence remains stable across treatment modalities and disease stages, suggesting that the tumor itself is the primary driver of thrombotic risk. The prevalence of NT-CVDs in PDAC is comparable to that in the general population and shows minimal variation across cancer stages or treatment modalities.
- Open Access
- 3 March 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (3) , 404-411
Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis
- 3 March 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (3) , 404-411
Open AccessRisk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis
- Open Access
- 15 February 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (2) , 117-129
Progression from acute to chronic pancreatitis in children: a systematic review and meta-analysis
Background: Most children recover after an initial acute pancreatitis (AP) episode; however, some progress to recurrent AP (RAP) or chronic pancreatitis (CP).Purpose: We aimed to quantify progression rates and identify the risk factors associated with these transitions.Methods: PubMed/MEDLINE, Embase, and Cochrane databases were searched on December 21, 2024, for pediatric studies reporting progression to RAP or CP (PROSPERO number: CRD420251086520). All observational studies were included, while case reports and case series were excluded. To evaluate the differences in RAP rates, we conducted subgroup analyses of etiology and severity. We also assessed clinical, structural, and genetic risk factors for disease progression. A random-effects model was used to pool proportions and odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity was assessed using the I² statistic.Results: A total of 68 studies met the inclusion criteria. After the first AP attack, RAP developed in 18% (95% CI, 16–22%; I2=76%; k=39 studies) and CP developed in 10% (95% CI, 6–16%; I2=67%; k=5 studies) of patients. Among children with RAP, 35% (95% CI, 24–49%; I2=78%; k=7 studies) progressed to CP. The RAP rates varied according to etiology and severity: hypertriglyceridemia, 33%; idiopathic, 28%; biliary, 19%; traumatic, 16%; drug-induced, 14%; virus-induced, 3%; severe, 39%; moderate, 24%; and mild, 21%. Structural abnormalities were associated with a higher risk of RAP (OR, 3.15; 95% CI, 1.51–6.56; I2=0%; k=5 studies). Pancreas divisum (OR, 2.64; 95% CI, 1.51–4.63; I2=17%; k=7 studies) and PRSS1 mutation (OR: 4.56; 95% CI, 3.06–6.80; I2=0%; k=7 studies) were associated with CP.Conclusion: Approximately one in five pediatric AP episodes recurred, and over one-third of the RAP cases progressed to CP. The risk of RAP is influenced by the underlying etiology and severity of the initial episode, whereas structural and genetic factors are associated with later progression.
- 15 February 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (2) , 117-129
Open AccessProgression from acute to chronic pancreatitis in children: a systematic review and meta-analysis
Background: Most children recover after an initial acute pancreatitis (AP) episode; however, some progress to recurrent AP (RAP) or chronic pancreatitis (CP).Purpose: We aimed to quantify progression rates and identify the risk factors associated with these transitions.Methods: PubMed/MEDLINE, Embase, and Cochrane databases were searched on December 21, 2024, for pediatric studies reporting progression to RAP or CP (PROSPERO number: CRD420251086520). All observational studies were included, while case reports and case series were excluded. To evaluate the differences in RAP rates, we conducted subgroup analyses of etiology and severity. We also assessed clinical, structural, and genetic risk factors for disease progression. A random-effects model was used to pool proportions and odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity was assessed using the I² statistic.Results: A total of 68 studies met the inclusion criteria. After the first AP attack, RAP developed in 18% (95% CI, 16–22%; I2=76%; k=39 studies) and CP developed in 10% (95% CI, 6–16%; I2=67%; k=5 studies) of patients. Among children with RAP, 35% (95% CI, 24–49%; I2=78%; k=7 studies) progressed to CP. The RAP rates varied according to etiology and severity: hypertriglyceridemia, 33%; idiopathic, 28%; biliary, 19%; traumatic, 16%; drug-induced, 14%; virus-induced, 3%; severe, 39%; moderate, 24%; and mild, 21%. Structural abnormalities were associated with a higher risk of RAP (OR, 3.15; 95% CI, 1.51–6.56; I2=0%; k=5 studies). Pancreas divisum (OR, 2.64; 95% CI, 1.51–4.63; I2=17%; k=7 studies) and PRSS1 mutation (OR: 4.56; 95% CI, 3.06–6.80; I2=0%; k=7 studies) were associated with CP.Conclusion: Approximately one in five pediatric AP episodes recurred, and over one-third of the RAP cases progressed to CP. The risk of RAP is influenced by the underlying etiology and severity of the initial episode, whereas structural and genetic factors are associated with later progression.
- Open Access
- 23 January 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 221-230
High prevalence of anxiety and depression among patients with acute and chronic pancreatitis: A systematic review and meta-analysis
- 23 January 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (2) , 221-230
Open AccessHigh prevalence of anxiety and depression among patients with acute and chronic pancreatitis: A systematic review and meta-analysis